{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:03Z","timestamp":1791976503539,"version":"4.4.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,12,3]],"date-time":"2008-12-03T00:00:00Z","timestamp":1228262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s00277-008-0645-y","type":"journal-article","created":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T16:20:47Z","timestamp":1228234847000},"page":"193-201","source":"Crossref","is-referenced-by-count":104,"title":["Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities"],"prefix":"10.1007","volume":"88","author":[{"given":"Yok-Lam","family":"Kwong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic Y. M.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce C. W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,3]]},"reference":[{"key":"645_CR1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(08)70070-6","volume":"9","author":"CH Pui","year":"2008","unstructured":"Pui CH, Howard SC (2008) Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 9:257\u2013268 doi: 10.1016\/S1470-2045(08)70070-6","journal-title":"Lancet Oncol"},{"key":"645_CR2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2141.2005.05756.x","volume":"131","author":"CW Cheung","year":"2005","unstructured":"Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM (2005) Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 131:193\u2013200 doi: 10.1111\/j.1365-2141.2005.05756.x","journal-title":"Br J Haematol"},{"key":"645_CR3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","volume":"25","author":"LL Muldoon","year":"2007","unstructured":"Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, Neuwelt EA (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295\u20132305 doi: 10.1200\/JCO.2006.09.9861","journal-title":"J Clin Oncol"},{"key":"645_CR4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1983.1.9.546","volume":"1","author":"ML Slevin","year":"1983","unstructured":"Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA (1983) Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1:546\u2013551","journal-title":"J Clin Oncol"},{"key":"645_CR5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02228887","volume":"3","author":"JA Lopez","year":"1985","unstructured":"Lopez JA, Nassif E, Vannicola P, Krikorian JG, Agarwal RP (1985) Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 3:119\u2013124 doi: 10.1007\/BF02228887","journal-title":"J Neurooncol"},{"key":"645_CR6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00686248","volume":"29","author":"LM DeAngelis","year":"1992","unstructured":"DeAngelis LM, Kreis W, Chan K, Dantis E, Akerman S (1992) Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother Pharmacol 29:173\u2013177 doi: 10.1007\/BF00686248","journal-title":"Cancer Chemother Pharmacol"},{"key":"645_CR7","first-page":"5037","volume":"23","author":"H Sutoh","year":"2003","unstructured":"Sutoh H, Yamauchi T, Gotoh N, Sugiyama M, Ueda T (2003) Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia. Anticancer Res 23:5037\u20135042","journal-title":"Anticancer Res"},{"key":"645_CR8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10428199409049660","volume":"14","author":"F Millot","year":"1994","unstructured":"Millot F, Rubie H, Mazingue F, Mechinaud F, Thyss A (1994) Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5\u00a0g\/m2 methotrexate. Leuk Lymphoma 14:141\u2013144 doi: 10.3109\/10428199409049660","journal-title":"Leuk Lymphoma"},{"key":"645_CR9","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/1097-0142(19821101)50:9<1676::AID-CNCR2820500903>3.0.CO;2-S","volume":"50","author":"LJ Ettinger","year":"1982","unstructured":"Ettinger LJ, Chervinsky DS, Freeman AI, Creaven PJ (1982) Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin\u2019s lymphoma. Cancer 50:1676\u20131682 doi: 10.1002\/1097-0142(19821101)50:9<1676::AID-CNCR2820500903>3.0.CO;2-S","journal-title":"Cancer"},{"key":"645_CR10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/08880018809031261","volume":"5","author":"RJ Lippens","year":"1988","unstructured":"Lippens RJ, Winograd B (1988) Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol 5:115\u2013124 doi: 10.3109\/08880018809031261","journal-title":"Pediatr Hematol Oncol"},{"key":"645_CR11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002800000118","volume":"46","author":"ML Tetef","year":"2000","unstructured":"Tetef ML, Margolin KA, Doroshow JH, Akman S, Leong LA, Morgan RJ Jr, Raschko JW, Slatkin N, Somlo G, Longmate JA, Carroll MI, Newman EM (2000) Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46:19\u201326 doi: 10.1007\/s002800000118","journal-title":"Cancer Chemother Pharmacol"},{"key":"645_CR12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1067\/mcp.2000.106932","volume":"67","author":"E Zylber-Katz","year":"2000","unstructured":"Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T (2000) Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood\u2013brain barrier disruption in patients with brain lymphoma. Clin Pharmacol Ther 67:631\u2013641 doi: 10.1067\/mcp.2000.106932","journal-title":"Clin Pharmacol Ther"},{"key":"645_CR13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/annonc\/2.suppl_2.63","volume":"2","author":"M Zucchetti","year":"1991","unstructured":"Zucchetti M, Rossi C, Knerich R, Donelli MG, Butti G, Silvani V, Gaetani P, D\u2019Incalci M (1991) Concentrations of VP16 and VM26 in human brain tumors. Ann Oncol 2:63\u201366","journal-title":"Ann Oncol"},{"key":"645_CR14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1996.14.2.399","volume":"14","author":"MV Relling","year":"1996","unstructured":"Relling MV, Mahmoud HH, Pui CH, Sandlund JT, Rivera GK, Ribeiro RC, Crist WM, Evans WE (1996) Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol 14:399\u2013404","journal-title":"J Clin Oncol"},{"key":"645_CR15","first-page":"6525","volume":"50","author":"JM Reid","year":"1990","unstructured":"Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children\u2019s Cancer Study Group report. Cancer Res 50:6525\u20136528","journal-title":"Cancer Res"},{"key":"645_CR16","first-page":"1985","volume":"3","author":"SM Yule","year":"1997","unstructured":"Yule SM, Price L, Pearson AD, Boddy AV (1997) Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res 3:1985\u20131992","journal-title":"Clin Cancer Res"},{"key":"645_CR17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/BF00257448","volume":"24","author":"G Vassal","year":"1989","unstructured":"Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J (1989) Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 24:386\u2013390 doi: 10.1007\/BF00257448","journal-title":"Cancer Chemother Pharmacol"},{"key":"645_CR18","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/cncr.10397","volume":"94","author":"SJ Kellie","year":"2002","unstructured":"Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr DJ, de Graaf SS (2002) Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer 94:1815\u20131820 doi: 10.1002\/cncr.10397","journal-title":"Cancer"},{"key":"645_CR19","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood-2008-06-161000","volume":"112","author":"WY Au","year":"2008","unstructured":"Au WY, Tam S, Fong BM, Kwong YL (2008) Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 112:3587\u20133590","journal-title":"Blood"},{"key":"645_CR20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.V55.2.199.199","volume":"55","author":"GA Omura","year":"1980","unstructured":"Omura GA, Moffitt S, Vogler WR, Salter MM (1980) Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 55:199\u2013204","journal-title":"Blood"},{"key":"645_CR21","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"RA Larson","year":"1995","unstructured":"Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, Hooberman AL, Westbrook CA, Arthur DC, George SL, Bloomfield CD, Schiffer CA (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85:2025\u20132037","journal-title":"Blood"},{"key":"645_CR22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V37.3.272.272","volume":"37","author":"RJ Aur","year":"1971","unstructured":"Aur RJ, Simone J, Hustu HO, Walters T, Borella L, Pratt C, Pinkel D (1971) Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 37:272\u2013281","journal-title":"Blood"},{"key":"645_CR23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O\u2019Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569\u20131580 doi: 10.1002\/cncr.21776","journal-title":"Cancer"},{"key":"645_CR24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.leu.2404006","volume":"20","author":"S Botton de","year":"2006","unstructured":"de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD, Recher C, Ades L, Quesnel B, Brault P, Fey M, Wandt H, Machover D, Guerci A, Maloisel F, Stoppa AM, Rayon C, Ribera JM, Chomienne C, Degos L, Fenaux P, European APL Group; PETHEMA Group (2006) Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 20:35\u201341 doi: 10.1038\/sj.leu.2404006","journal-title":"Leukemia"},{"key":"645_CR25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.blre.2006.02.001","volume":"20","author":"QA Hill","year":"2006","unstructured":"Hill QA, Owen RG (2006) CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 20:319\u2013332 doi: 10.1016\/j.blre.2006.02.001","journal-title":"Blood Rev"},{"key":"645_CR26","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2007.10.8464","volume":"25","author":"DP Waber","year":"2007","unstructured":"Waber DP, Turek J, Catania L, Stevenson K, Robaey P, Romero I, Adams H, Alyman C, Jandet-Brunet C, Neuberg DS, Sallan SE, Silverman LB (2007) Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18\u00a0Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol 25:4914\u20134921 doi: 10.1200\/JCO.2007.10.8464","journal-title":"J Clin Oncol"},{"key":"645_CR27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547\u2013561","journal-title":"J Clin Oncol"},{"key":"645_CR28","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2002-08-2372","volume":"102","author":"DO Harms","year":"2003","unstructured":"Harms DO, G\u00f6bel U, Spaar HJ, Graubner UB, Jorch N, Gutjahr P, Janka-Schaub GE, COALL Study Group (2003) Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 102:2736\u20132740 doi: 10.1182\/blood-2002-08-2372","journal-title":"Blood"},{"key":"645_CR29","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","volume":"109","author":"A Moghrabi","year":"2007","unstructured":"Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896\u2013904 doi: 10.1182\/blood-2006-06-027714","journal-title":"Blood"},{"key":"645_CR30","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2401960","volume":"14","author":"E Vilmer","year":"2000","unstructured":"Vilmer E, Suciu S, Ferster A, Bertrand Y, Cav\u00e9 H, Thyss A, Benoit Y, Dastugue N, Fournier M, Souillet G, Manel AM, Robert A, Nelken B, Millot F, Lutz P, Rialland X, Mechinaud F, Boutard P, Behar C, Chantraine JM, Plouvier E, Laureys G, Brock P, Uyttebroeck A, Margueritte G, Plantaz D, Norton L, Francotte N, Gyselinck J, Waterkeyn C, Solbu G, Philippe N, Otten J (2000) Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 14:2257\u20132266 doi: 10.1038\/sj.leu.2401960","journal-title":"Leukemia"},{"key":"645_CR31","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1182\/blood-2004-04-1616","volume":"104","author":"CH Pui","year":"2004","unstructured":"Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, Rubnitz JE, Razzouk BI, Howard SC, Hudson MM, Cheng C, Kun LE, Raimondi SC, Behm FG, Downing JR, Relling MV, Evans WE, Total Therapy Study XIIIB at St Jude Children\u2019s Research Hospital (2004) Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children\u2019s Research Hospital. Blood 104:2690\u20132696 doi: 10.1182\/blood-2004-04-1616","journal-title":"Blood"},{"key":"645_CR32","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(06)69558-5","volume":"368","author":"A Vora","year":"2006","unstructured":"Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, Richards SM, Medical Research Council; National Cancer Research Network Childhood Leukaemia Working Party (2006) Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 368:1339\u20131348 doi: 10.1016\/S0140-6736(06)69558-5","journal-title":"Lancet"},{"key":"645_CR33","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","volume":"111","author":"A M\u00f6ricke","year":"2008","unstructured":"M\u00f6ricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, D\u00f6rdelmann M, L\u00f6ning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M, German\u2013Austrian\u2013Swiss ALL-BFM Study Group (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477\u20134489 doi: 10.1182\/blood-2007-09-112920","journal-title":"Blood"},{"key":"645_CR34","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH, ECOG; MRC\/NCRI adult leukemia working party (2005) Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood 106:3760\u20133767 doi: 10.1182\/blood-2005-04-1623","journal-title":"Blood"},{"key":"645_CR35","first-page":"1556","volume":"92","author":"RA Larson","year":"1998","unstructured":"Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA (1998) A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92:1556\u20131564","journal-title":"Blood"},{"key":"645_CR36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Peta A, Ciolli S, Deplano W, Fabbiano F, Sica S, Di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F, GIMEMA Group (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99:863\u2013871 doi: 10.1182\/blood.V99.3.863","journal-title":"Blood"},{"key":"645_CR37","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","volume":"20","author":"C Linker","year":"2002","unstructured":"Linker C, Damon L, Ries C, Navarro W (2002) Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 20:2464\u20132471 doi: 10.1200\/JCO.2002.07.116","journal-title":"J Clin Oncol"},{"key":"645_CR38","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","volume":"22","author":"X Thomas","year":"2004","unstructured":"Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lh\u00e9ritier V, Fiere D (2004) Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22:4075\u20134086 doi: 10.1200\/JCO.2004.10.050","journal-title":"J Clin Oncol"},{"key":"645_CR39","first-page":"703","volume":"61","author":"WA Bleyer","year":"1977","unstructured":"Bleyer WA, Dedrick RL (1977) Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61:703\u2013708","journal-title":"Cancer Treat Rep"},{"key":"645_CR40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00003088-198005050-00004","volume":"5","author":"J Lankelma","year":"1980","unstructured":"Lankelma J, Lippens RJ, Drenthe-Schonk A, Termond EF, van der Kleijn E (1980) Change in transfer rate of methotrexate from spinal fluid to plasma during intrathecal therapy in children and adults. Clin Pharmacokinet 5:465\u2013475","journal-title":"Clin Pharmacokinet"},{"key":"645_CR41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00043426-200302000-00006","volume":"25","author":"BC Bostrom","year":"2003","unstructured":"Bostrom BC, Erdmann GR, Kamen BA (2003) Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol 25:114\u2013117 doi: 10.1097\/00043426-200302000-00006","journal-title":"J Pediatr Hematol Oncol"},{"key":"645_CR42","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/1097-0142(197610)38:4<1529::AID-CNCR2820380414>3.0.CO;2-E","volume":"38","author":"PH Gutin","year":"1976","unstructured":"Gutin PH, Green MR, Bleyer WA, Bauer VL, Wiernik PH, Walker MD (1976) Methotrexate pneumonitis induced by intrathecal methotrexate therapy: a case report with pharmacokinetic data. Cancer 38:1529\u20131534 doi: 10.1002\/1097-0142(197610)38:4<1529::AID-CNCR2820380414>3.0.CO;2-E","journal-title":"Cancer"},{"key":"645_CR43","first-page":"999","volume":"5","author":"RE Gregory","year":"1991","unstructured":"Gregory RE, Pui CH, Crom WR (1991) Raised plasma methotrexate concentrations following intrathecal administration in children with renal dysfunction. Leukemia 5:999\u20131003","journal-title":"Leukemia"},{"key":"645_CR44","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","volume":"13","author":"GM Mead","year":"2002","unstructured":"Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, Guarnaccia C, Lewis MS, McKendrick J, Stenning SP, Wright D, UKLG LY06 collaborators (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264\u20131274 doi: 10.1093\/annonc\/mdf253","journal-title":"Ann Oncol"},{"key":"645_CR45","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1200\/JCO.1993.11.11.2186","volume":"11","author":"S Kim","year":"1993","unstructured":"Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA, Chamberlain MC (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11:2186\u20132193","journal-title":"J Clin Oncol"},{"key":"645_CR46","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","volume":"17","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110\u20133116","journal-title":"J Clin Oncol"},{"key":"645_CR47","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","volume":"109","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, O\u2019Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109:3214\u20133218 doi: 10.1182\/blood-2006-08-043646","journal-title":"Blood"},{"key":"645_CR48","first-page":"92","volume":"160","author":"R Marshall","year":"2008","unstructured":"Marshall R, Gupta ND, Palacios E, Neitzschman HR (2008) Progressive paresthesia and weakness after intrathecal chemotherapy. J La State Med Soc 160:92\u201394","journal-title":"J La State Med Soc"},{"key":"645_CR49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3349\/ymj.2008.49.1.151","volume":"49","author":"HY Lee","year":"2008","unstructured":"Lee HY, Im SI, Kang MH, Kim KM, Kim SH, Kim HG, Kang JH, Lee GW (2008) Irreversible paraplegia following one time prophylactic intrathecal chemotherapy in an adult patient with acute lymphoblastic leukemia. Yonsei Med J 49:151\u2013154 doi: 10.3349\/ymj.2008.49.1.151","journal-title":"Yonsei Med J"},{"key":"645_CR50","first-page":"e46","volume":"48","author":"HS Teh","year":"2007","unstructured":"Teh HS, Fadilah SA, Leong CF (2007) Transverse myelopathy following intrathecal administration of chemotherapy. Singapore Med J 48:e46\u2013e49","journal-title":"Singapore Med J"},{"key":"645_CR51","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.crad.2006.09.005","volume":"62","author":"P Counsel","year":"2007","unstructured":"Counsel P, Khangure M (2007) Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings. Clin Radiol 62:172\u2013176 doi: 10.1016\/j.crad.2006.09.005","journal-title":"Clin Radiol"},{"key":"645_CR52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.mph.0000162527.85024.e9","volume":"27","author":"A Bay","year":"2005","unstructured":"Bay A, Oner AF, Etlik O, Yilmaz C, Caksen H (2005) Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol 27:270\u2013272 doi: 10.1097\/01.mph.0000162527.85024.e9","journal-title":"J Pediatr Hematol Oncol"},{"key":"645_CR53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s002770050450","volume":"77","author":"G Massenkeil","year":"1998","unstructured":"Massenkeil G, Sp\u00e4th-Schwalbe E, Flath B, Gottschalk S, Lehmann R, Arnold R (1998) Transient tetraparesis after intrathecal and high-dose systemic methotrexate. Ann Hematol 77:239\u2013242 doi: 10.1007\/s002770050450","journal-title":"Ann Hematol"},{"key":"645_CR54","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1002\/1097-0142(19941201)74:11<3034::AID-CNCR2820741122>3.0.CO;2-O","volume":"74","author":"J Watterson","year":"1994","unstructured":"Watterson J, Toogood I, Nieder M, Morse M, Frierdich S, Lee Y, Moertel CL, Priest JR (1994) Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 74:3034\u20133041 doi: 10.1002\/1097-0142(19941201)74:11<3034::AID-CNCR2820741122>3.0.CO;2-O","journal-title":"Cancer"},{"key":"645_CR55","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/1097-0142(19921115)70:10<2504::AID-CNCR2820701019>3.0.CO;2-H","volume":"70","author":"BK Kleinschmidt-DeMasters","year":"1992","unstructured":"Kleinschmidt-DeMasters BK, Yeh M (1992) \u201cLocked-in syndrome\u201d after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer 70:2504\u20132507 doi: 10.1002\/1097-0142(19921115)70:10<2504::AID-CNCR2820701019>3.0.CO;2-H","journal-title":"Cancer"},{"key":"645_CR56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mpo.2950130103","volume":"13","author":"SE Bates","year":"1985","unstructured":"Bates SE, Raphaelson MI, Price RA, McKeever P, Cohen S, Poplack DG (1985) Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: correlation with cerebrospinal fluid myelin basic protein. Med Pediatr Oncol 13:4\u20138 doi: 10.1002\/mpo.2950130103","journal-title":"Med Pediatr Oncol"},{"key":"645_CR57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1097-0142(19930101)71:1<117::AID-CNCR2820710119>3.0.CO;2-K","volume":"71","author":"LM Resar","year":"1993","unstructured":"Resar LM, Phillips PC, Kastan MB, Leventhal BG, Bowman PW, Civin CI (1993) Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 71:117\u2013123 doi: 10.1002\/1097-0142(19930101)71:1<117::AID-CNCR2820710119>3.0.CO;2-K","journal-title":"Cancer"},{"key":"645_CR58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MPH.0b013e3180335043","volume":"29","author":"CM Pound","year":"2007","unstructured":"Pound CM, Keene DL, Udjus K, Humphreys P, Johnston DL (2007) Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 29:183\u2013186 doi: 10.1097\/MPH.0b013e3180335043","journal-title":"J Pediatr Hematol Oncol"},{"key":"645_CR59","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1038\/sj.leu.2402569","volume":"16","author":"F Legrand","year":"2002","unstructured":"Legrand F, Dorgeret S, Saizou C, Duval M, Vilmer E (2002) Cerebellar herniation after intrathecal chemotherapy including cytosine arabinoside in a boy with T acute lymphoblastic leukemia. Leukemia 16:2454\u20132455 doi: 10.1038\/sj.leu.2402569","journal-title":"Leukemia"},{"key":"645_CR60","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.leu.2404495","volume":"21","author":"MN Dufourg","year":"2007","unstructured":"Dufourg MN, Landman-Parker J, Auclerc MF, Schmitt C, Perel Y, Michel G, Levy P, Couillault G, Gandemer V, Tabone MD, Demeocq F, Vannier JP, Leblanc T, Leverger G, Baruchel A (2007) Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children. Leukemia 21:238\u2013247 doi: 10.1038\/sj.leu.2404495","journal-title":"Leukemia"},{"key":"645_CR61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2141.2005.05756.x","volume":"131","author":"CW Cheung","year":"2005","unstructured":"Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM (2005) Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 131:193\u2013200 doi: 10.1111\/j.1365-2141.2005.05756.x","journal-title":"Br J Haematol"},{"key":"645_CR62","doi-asserted-by":"crossref","unstructured":"Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E (2008) Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol Aug 5. In press","DOI":"10.1007\/s00277-008-0575-8"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0645-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-008-0645-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0645-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T08:59:05Z","timestamp":1589273945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0645-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0645-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,3]]}}}